Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is intended to provide clinical data regarding safety and accuracy of the ActiSightâ„¢ Needle Guidance System in assisting Chest CT guided biopsies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biopsy needle guidance system (ActiSightâ„¢) | Device | The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of target reached within a radius of 8 mm from the preplanned targeted point as measured on the final CT scan. | Measure evaluated during entire course of study |
| Measure | Description | Time Frame |
|---|---|---|
| Number of needle punctures through the skin | Measure evaluated during entire course of study | |
| Number of needle punctures through the pleura | Measure evaluated during entire course of study | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Fibrous tissue or cyst in access path (not including target lesion)
Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting
Central lesion is located in radius of less than 2 cm from lobar blood vessels and the heart.
The selected needle path has a safety margin of less than 2 cm from major blood vessels and the heart
Use of ticlopidine or similar antithrombotic medication
For subjects taking warfarin or other anticoagulant medication, INR >1.3
Pulmonary hypertension, heart failure, renal failure, or blood dyscrasia
Subjects who cannot tolerate mild sedation
Subjects with FEV1 < 800 mL unless approved by principal investigator following consultation with multidisciplinary team
Subjects with the following laboratory values, unless approved by hematologist:
Pregnancy or lactation
Patient is unable to comply with requirements of the procedure, i.e. holding breath
Participation in an investigational trial within 30 days of enrollment
Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study.
Subjects who are uncooperative or cannot follow instructions
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boaz Tiran, MD | Tel-Aviv Sourasky Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of CT scans needed |
| Measure evaluated during entire course of study |
| Radial distance at target plane at the needle's final position as shown on the ActiSight screen | Measure evaluated during entire course of study |
| Adverse events following the procedure, including the following:Pneumothorax, Hemoptysis >100 ml, Bleeding, Collapsed lung, Chest drainage, Need for hospitalization | Measure evaluated during entire course of study |